Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
Menée sur des lignées cellulaires et à l'aide de modèles murins, cette étude identifie un mécanisme d'interaction synthétique léthale entre le nilotinib et des inhibiteurs de MEK et suggère que la combinaison de ces molécules permettrait de bloquer la croissance tumorale d'une leucémie myéloïde chronique résistante à l'imatinib
We show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the presence of these drugs, driving paradoxical activation of BRAF, CRAF, MEK, and ERK, and leading to an unexpected dependency on the pathway. Consequently, nilotinib synergizes with MEK inhibitors to kill drug-resistant CML cells and block tumor growth in mice. Thus, we show that imatinib, nilotinib, and dasatinib drive paradoxical RAF/MEK/ERK pathway activation and have uncovered a synthetic lethal interaction that can be used to kill drug-resistant CML cells in vitro and in vivo. º Imatinib, nilotinib, and dasatinib are RAF inhibitors º Nilotinib drives paradoxically activation of RAF in drug-resistant CML cells º Nilotinib and MEK inhibitors synergize to kill drug-resistant CML cells in vitro º Nilotinib and MEK inhibitors synergize to block drug-resistant CML tumor growth